Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease

Diabetes Care

Volumn 36, Issue 6, 2013, Pages 1654-1659

  Rahmi, Rosa Maria ^a   Uchida, Augusto Hiroshi ^a   Rezende, Paulo Cury ^a   Lima, Eduardo Gomes ^a   Garzillo, Cibele Larrosa ^a   Favarato, Desiderio ^a   Strunz, Celia M C ^a   Takiuti, Myrthes ^a   Girardi, Priscyla ^a   Hueb, Whady ^a   Kalil Filho, Roberto ^a   Ramires, José A F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

REPAGLINIDE; VILDAGLIPTIN;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; EXERCISE TEST; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC PRECONDITIONING; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; ST SEGMENT DEPRESSION;

ADAMANTANE; AGED; CARBAMATES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; ISCHEMIC PRECONDITIONING; MALE; MIDDLE AGED; NITRILES; PIPERIDINES; PROSPECTIVE STUDIES; PYRROLIDINES;

EID: 84878232947     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1495     Document Type: Article

References (40)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136 (Pubitemid 17174962)
2. Tomai F, Crea F, Chiariello L, Gioffrè PA. Ischemic preconditioning in humans: models, mediators, and clinical relevance. Circulation 1999;100:559-563 (Pubitemid 29360167)
3. Okazaki Y, Kodama K, Sato H, et al. Attenuation of increased regional myocardial oxygen consumption during exercise as a major cause of warm-up phenomenon. J Am Coll Cardiol 1993;21:1597-1604 (Pubitemid 23170432)
4. Jaffe MD, Quinn NK. Warm-up phenomenon in angina pectoris. Lancet 1980;2:934-936 (Pubitemid 11240457)
5. Waters DD, McCans JL, Crean PA. Serial exercise testing in patients with effort angina: variable tolerance, fixed threshold. J Am Coll Cardiol 1985;6:1011-1015 (Pubitemid 16219195)
6. Stewart RA, Simmonds MB, Williams MJ. Time course of "warm-up" in stable angina. Am J Cardiol 1995;76:70-73
7. Maybaum S, Ilan M, Mogilevsky J, Tzivoni D. Improvement in ischemic parameters during repeated exercise testing: a possible model for myocardial preconditioning. Am J Cardiol 1996;78:1087-1091 (Pubitemid 126657167)
8. Tomai F. Warm up phenomenon and preconditioning in clinical practice. Heart 2002;87:99-100 (Pubitemid 34098364)
9. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113-1151 (Pubitemid 37222269)
10. Gross GJ, Peart JN. KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 2003;285:H921-H930 (Pubitemid 37048144)
11. Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997;96:29-32 (Pubitemid 27298399)
12. Tomai F, Danesi A, Ghini AS, et al. Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon. Eur Heart J 1999;20:196-202 (Pubitemid 29077940)
13. Ovünç K. Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin Cardiol 2000;23:535-539 (Pubitemid 30437646)
14. Ferreira BM, Moffa PJ, Falcão A, et al. The effects of glibenclamide, a K(ATP) channel blocker, on the warm-up phenomenon. Ann Noninvasive Electrocardiol 2005;10:356-362 (Pubitemid 41152929)
15. Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 2000;49(Suppl. 2):3-6
16. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999;20:439-446 (Pubitemid 29116540)
17. Bilinska M, Potocka J, Korzeniowska-Kubacka I, Piotrowicz R. 'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas. Coron Artery Dis 2007;18:455-462 (Pubitemid 47262967)
18. Dabrowski M, Wahl P, Holmes WE, Ashcroft FM. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 2001;44:747-756 (Pubitemid 32846030)
19. Stephan D, Winkler M, Kühner P, Russ U, Quast U. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels. Diabetologia 2006;49:2039-2048 (Pubitemid 44168470)
20. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-1343 (Pubitemid 46871135)
21. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-224
22. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187-215
23. Hueb W, Uchida AH, Gersh BJ, et al. Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris. Coron Artery Dis 2007;18:55-59 (Pubitemid 44973757)
24. Tomai F, Crea F, Danesi A, et al. Mechanisms of the warm-up phenomenon. Eur Heart J 1996;17:1022-1027 (Pubitemid 26252519)
25. Gobel FL, Norstrom LA, Nelson RR, Jorgensen CR, Wang Y. The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation 1978;57:549-556 (Pubitemid 8284533)
26. Rizi HR, Kline RC, Besozzi MC, et al. Walk-through angina phenomenon demonstrated by graded exercise radionuclide ventriculography: possible coronary spasm mechanisms. Am Heart J 1982;103:292-295
27. Ylitalo K, Jama L, Raatikainen P, Peuhkurinen K. Adaptation to myocardial ischemia during repeated dynamic exercise in relation to findings at cardiac catheterization. Am Heart J 1996;131:689-697 (Pubitemid 26119561)
28. Williams DO, Bass TA, Gewirtz H, Most AS. Adaptation to the stress of tachycardia in patients with coronary artery disease: insight into the mechanism of the warm-up phenomenon. Circulation 1985;71:687-692 (Pubitemid 15099117)
29. Gross GJ. ATP-sensitive potassium channels and myocardial preconditioning. Basic Res Cardiol 1995;90:85-88
30. Suzuki M, Sasaki N, Miki T, et al. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest 2002;109:509-516 (Pubitemid 34171782)
31. Wei Y, Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 1996;157:355-357 (Pubitemid 126753443)
32. Fryer RM, Auchampach JA, Gross GJ. Therapeutic receptor targets of ischemic preconditioning. Cardiovasc Res 2002;55:520-525 (Pubitemid 34874946)
33. Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005;19:9-11 (Pubitemid 40767767)
34. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-983
35. Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006;317:1106-1113 (Pubitemid 43764114)
36. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965 (Pubitemid 38282847)
37. Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-1073
38. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010;298:H1454-H1465
39. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3:195-201
40. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900-1908